Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05337254 · ClinicalTrials.gov registry record · Phase 1
A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
A Phase 1 study, sponsored by Satsuma Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT05337254 is a Phase 1 study that has completed, run by Satsuma Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT05337254, a Phase 1 study, has completed, sponsored by Satsuma Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Single-center, single-dose, open-label, 5-period crossover (in each part), pharmacokinetic and safety study.
Interventions
- DRUG Dihydroergotamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2021-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05337254
The ClinicalTrials.gov registry entry for NCT05337254 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Satsuma Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dihydroergotamine is the first listed.
NCT05337254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05337254 about?
NCT05337254 is a clinical study titled "A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects". Single-center, single-dose, open-label, 5-period crossover (in each part), pharmacokinetic and safety study.
What is the current status of trial NCT05337254?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-03-05. Estimated completion is 2021-06-04.
What interventions are being tested in trial NCT05337254?
The interventions under investigation include: Dihydroergotamine (DRUG).
Who is sponsoring clinical trial NCT05337254?
This trial is sponsored by Satsuma Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.